Roche’s breast cancer agreement with Astex is one of several oncology deals the Swiss pharma giant has inked in recent years.

Roche's Genentech unit has forged an alliance with Astex, worth up to $515 million, to partner on a fragment-based drug ...

Collaboration leverages Astex’s industry-leading, fragment-based drug discovery capability to target a key cell-cycle-dependent regulator in breast cancerAstex to receive an upfront and potential ...

Cambridge Science Park-based Astex Pharmaceuticals has signed a breast cancer drug discovery deal with Genentech that could ...

Astex Pharmaceuticals on Cambridge Science Park has tapped into a gold mine through a mega-deal with Genentech, a member of ...

A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed ...

ASTX528 is a novel small molecule CBP/p300 HAT domain inhibitor with potent in vivo activity and a favourable safety profile in preclinical species that was discovered by Astex using its proprietary ...

A major five-year strategic drug discovery alliance, to discover and develop new cancer drugs, has been formed by Astex Pharmaceuticals, Cancer Research Technology Limited and Newcastle University.

The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic ...

In the latest buyout of what’s been a busy M&A week, Japanese drug maker Otsuka inked an $886 million pact on Thursday to snag U.S. cancer treatment maker Astex (NASDAQ:ASTX). The deal will allow ...

Astex signs research collaboration and license agreement with Genentech for breast cancer therapy: Cambridge, UK Tuesday, July 7, 2026, 16:00 Hrs [IST] Astex Pharmaceuticals, a wh ...